GRANULES Granules India Q1 FY27 results (Apr–Jun 2026) and concall
Granules India Limited delivered its strongest Q1 FY27 performance with revenue up 22% and PAT up 60%, driven by a strategic shift towards complex generics and strong margin expansion. The company achieved a near debt-free status with robust operating cash flow. While facing raw material pressures and awaiting FDA clearance for its Gagillapur facility, Granules is scaling its Peptide CDMO platform and investing in a differentiated product pipeline for future growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue down 1.0%, net profit up 4.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 568 | 842 | 768 | 810 | 892 +57% | 895 +6% | 877 +14% | 802 −1% |
| EBITDA | 103 | 168 | 117 | 144 | 211 +105% | 194 +15% | 175 +50% | 131 −9% |
| Net profit | 41 | 90 | 94 | 69 | 121 +195% | 112 +24% | 99 +5% | 72 +4% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
